Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2019 | Story Xolisa Mnukwa | Photo Supplied
Student Awards
The UFS rewarded student leaders for their hard work through the Division of Student Affairs (DSA) Student Leadership Awards (SALA).


The University of the Free State (UFS) Division of Student Affairs has recognised and awarded a number of student leaders in the areas of student life, arts and governance through the 2019 Student Affairs Leadership and Achievement Awards (SALA). 

Through SALA, the DSA aims to recognise and promote outstanding student leadership, thereby alleviating the threat of financial exclusion, which has been identified as a major challenge that students are currently facing. “With these awards, the department is making a small contribution towards mitigating such a challenge, especially for those students who are always at the forefront of student life, serving others while they themselves face similar challenges and contradictions,” explained Dean of Student Affairs, Pura Mgolombane.

The SALA committee convenes to select the student leaders to be awarded according to a definite rubric, which also determines the amount to be allocated. This year, the basic amount allocated was R6 000, whereas the highest amount was R25 000. The financial aspect of SALA is meant to assist students to pay for their tuition fees, with the money being paid directly into the student accounts. 

The rewards honour and incentivise students who have held leadership offices and impacted either the UFS Bloemfontein, South or Qwaqwa campuses and/or the student community of the university in a generally positive manner.

According to Mgolombane, the founder of the UFS Next Chapter organisation, Tshepang Mahlatsi, was one of the student leaders who was recognised as a leader deserving of an award amounting to R25 000 for his participation as a leader in various aspects of student life, from leading within UFS residences, to the Faculty of Law, and as an avid mental-health advocate. 

A total of 31 student leaders from the Bloemfontein Campus, 11 from the South Campus, 18 from the Qwaqwa Campus, and nine other students from all three campuses who outshone their peers, were SALA recipients in 2019. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept